[Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks(review)].
Recently published results of II and II phase clinical trials of alemtuzumab in relapsing-remitting multiple sclerosis (MS) are reviewed. This drug has an immunosuppressive mechanism of action with an anti-inflammatory effect higher than that of high-dose beta-interferon. Its neuroprotective activity and possible side-effects are discussed.